Jawień J, Lomnicka M, Korbut R, Chłopicki S
Jagiellonian University Medical College, Kraków, Poland.
J Physiol Pharmacol. 2005 Dec;56(4):637-48.
Platelet-leukocyte interactions represent an important determinant of the inflammatory response. Although mechanisms of platelet-neutrophil adhesion were studied extensively, little is known on the mechanisms of platelet-eosinophil interactions. The aim of the present study was to analyze the involvement of adhesion molecules and lipid mediators in platelet-eosinophil adhesion as compared to platelet-neutrophil adhesion. For that purpose human platelets, eosinophils and neutrophils were isolated and platelet-eosinophil and platelet-neutrophil adhesion induced by thrombin (30 mU/ml), LPS (0.01 microg/ml) and fMLP (1 microM) was quantified using the "rosettes" assay. The involvement of adhesion molecules such as selectin P, glycoprotein IIb/IIIa (GPIIb/IIIa) and lipid mediators such as of thromboxane A2 (TXA2), platelet activating factor (PAF) and cysteinyl leukotrienes (cysLTs) were studied using monoclonal antibodies and pharmacological inhibitors, respectively. Thrombin (30 mU/ml), LPS (0.01 microg/ml) and fMLP (1 microM) each of them induced platelet-eosinophil adhesion that was even more pronounced as compared with platelet-neutrophil adhesion induced by the same stimulus. Anti-CD62P antibody (1 microg/ml) and anti-GP IIb/IIIa antibody (abciximab-3 microg/ml) strongly inhibited platelet-eosinophil as well as platelet-neutrophil adhesion. Aspirin inhibited platelet-eosinophil adhesion, while MK 886-a FLAP inhibitor (10 microM), or WEB 2170-a PAF receptor antagonist (100 microM) were less active. On the other hand aspirin, MK 886 and WEB 2170 all three of them inhibited platelet-neutrophil adhesion. In summary, platelets adhered avidly to eosinophils both after activation of platelets by thrombin, eosinophils by fMLP or simultaneous activation of platelets and eosinophils by LPS. Similarly to platelet-neutrophil interaction adhesion of platelets to eosinophils involved not only adhesion molecules (selectin P, GPIIb/IIIa), but also lipid mediators such as TXA2. The involvement of PAF and cysteinyl leukotrienes in platelet-eosinophil adhesion was less pronounced as compared to platelet-neutrophil adhesion.
血小板与白细胞的相互作用是炎症反应的一个重要决定因素。尽管对血小板与中性粒细胞的黏附机制进行了广泛研究,但对于血小板与嗜酸性粒细胞相互作用的机制却知之甚少。本研究的目的是分析与血小板 - 中性粒细胞黏附相比,黏附分子和脂质介质在血小板 - 嗜酸性粒细胞黏附中的作用。为此,分离了人血小板、嗜酸性粒细胞和中性粒细胞,并使用“玫瑰花结”试验对凝血酶(30 mU/ml)、脂多糖(0.01 μg/ml)和N - 甲酰甲硫氨酸 - 亮氨酸 - 苯丙氨酸(fMLP,1 μM)诱导的血小板 - 嗜酸性粒细胞和血小板 - 中性粒细胞黏附进行定量。分别使用单克隆抗体和药理抑制剂研究了黏附分子如P - 选择素、糖蛋白IIb/IIIa(GPIIb/IIIa)以及脂质介质如血栓素A2(TXA2)、血小板活化因子(PAF)和半胱氨酰白三烯(cysLTs)的作用。凝血酶(30 mU/ml)、脂多糖(0.01 μg/ml)和fMLP(1 μM)均诱导了血小板 - 嗜酸性粒细胞黏附,与相同刺激诱导的血小板 - 中性粒细胞黏附相比更为明显。抗CD62P抗体(1 μg/ml)和抗GP IIb/IIIa抗体(阿昔单抗 - 3 μg/ml)强烈抑制血小板 - 嗜酸性粒细胞以及血小板 - 中性粒细胞黏附。阿司匹林抑制血小板 - 嗜酸性粒细胞黏附,而MK 886(一种FLAP抑制剂,10 μM)或WEB 2170(一种PAF受体拮抗剂,100 μM)活性较低。另一方面,阿司匹林、MK 886和WEB 2170均抑制血小板 - 中性粒细胞黏附。总之,在凝血酶激活血小板、fMLP激活嗜酸性粒细胞或脂多糖同时激活血小板和嗜酸性粒细胞后,血小板都能强烈黏附于嗜酸性粒细胞。与血小板 - 中性粒细胞相互作用类似,血小板与嗜酸性粒细胞的黏附不仅涉及黏附分子(P - 选择素、GPIIb/IIIa),还涉及脂质介质如TXA2。与血小板 - 中性粒细胞黏附相比,PAF和半胱氨酰白三烯在血小板 - 嗜酸性粒细胞黏附中的作用不太明显。